We are live on ! Find out more
PA

Perceptive Advisors Portfolio holdings

AUM $5.12B
1-Year Est. Return 314.02%
This Fund
S&P 500
This Quarter Est. Return
+26.22%
1 Year Est. Return
+314.02%
3 Year Est. Return
+1,498.66%
5 Year Est. Return
+2,457.67%
10 Year Est. Return
+48,821.41%
AUM
$1.23B
AUM Growth
+$240M
Cap. Flow
+$116M
Cap. Flow %
9.38%
Top 10 Hldgs %
61.25%
Holding
137
New
51
Increased
28
Reduced
20
Closed
23

Top Buys

Rank Stock Value
1
ONXX
ONYX PHARMACEUTICALS INC
ONXX
+$70.5M
2
CELG
Celgene Corp
CELG
+$37.6M
3
RPRX
Repros Therapeutics Inc.
RPRX
+$27.9M
4
TSRO
TESARO, Inc.
TSRO
+$21.7M
5
QCOR
QUESTCOR PHARMA INC
QCOR
+$19.9M

Top Sells

Rank Stock Value
1
AEGR
Aegerion Pharmaceuticals
AEGR
+$106M
2
BIIB icon
Biogen
BIIB
+$49.8M
3
REGN icon
Regeneron Pharmaceuticals
REGN
+$31.3M
4
STML
Stemline Therapeutics, Inc.
STML
+$16.4M
5
NBIX icon
Neurocrine Biosciences
NBIX
+$11.1M

Sector Composition

Rank Sector Weight
1 Healthcare 76.94%
2 Financials 0.01%
3 Consumer Staples 0.01%
4 Real Estate 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
EYPT icon
51
EyePoint Inc
EYPT
$999M
$3.17M 0.26%
+77,200
New +$2.85M
VSTM icon
52
Verastem
VSTM
$528M
$3M 0.24%
+20,089
New +$3.51M
MZOR
53
DELISTED
Mazor Robotics Ltd.
MZOR
$2.99M 0.24%
+177,078
New +$2.58M
MDVN
54
DELISTED
MEDIVATION, INC.
MDVN
$2.89M 0.23%
+96,500
New +$2.75M
LSTA icon
55
Lisata Therapeutics
LSTA
$9.93M
$2.83M 0.23%
2,211
– –
VVUS
56
PUT
DELISTED
Vivus Inc
VVUS
$2.69M 0.22%
+28,950
New +$3.61M
SPNC
57
DELISTED
Spectranetics Corp
SPNC
$2.59M 0.21%
154,079
-183,718
-54% -$3.2M
ECYT
58
PUT
DELISTED
Endocyte, Inc. Common Stock
ECYT
$2.57M 0.21%
+193,000
New +$3.05M
DXCM icon
59
DexCom
DXCM
$29B
$2.05M 0.17%
+290,200
New +$1.84M
KERX
60
DELISTED
Keryx Biopharmaceuticals Inc
KERX
$2.02M 0.16%
200,000
+150,000
+300% +$1.33M
MGCD
61
DELISTED
MGC Diagnostics Corporation
MGCD
$1.91M 0.16%
174,449
– –
ANTH
62
DELISTED
Anthera Pharmaceuticals, Inc.
ANTH
$1.73M 0.14%
53,932
– –
CLDX icon
63
CALL
Celldex Therapeutics
CLDX
$2.94B
$1.71M 0.14%
+3,220
New +$1.1M
MNKD icon
64
MannKind Corp
MNKD
$1.19B
$1.65M 0.13%
+57,900
New +$1.91M
BCRX icon
65
BioCryst Pharmaceuticals
BCRX
$2.42B
$1.39M 0.11%
+190,588
New +$967K
MYGN icon
66
CALL
Myriad Genetics
MYGN
$476M
$1.37M 0.11%
+58,300
New +$1.66M
GNMX
67
DELISTED
Aevi Genomic Medicine Inc
GNMX
$1.17M 0.1%
150,000
– –
ABUS icon
68
Arbutus Biopharma
ABUS
$847M
$1.11M 0.09%
159,309
-110,691
-41% -$609K
VNDA icon
69
PUT
Vanda Pharmaceuticals
VNDA
$304M
$1.06M 0.09%
+96,500
New +$1.03M
UPI
70
DELISTED
UROPLASTY INC-NEW
UPI
$1.01M 0.08%
303,989
+4,876
+2% +$13.6K
CASC
71
DELISTED
Cascadian Therapeutics, Inc.
CASC
$994K 0.08%
+80,417
New +$846K
AMRN
72
CALL
Amarin Corp
AMRN
$297M
$915K 0.07%
+7,240
New +$867K
PGNX
73
DELISTED
Progenics Pharmaceuticals Inc
PGNX
$849K 0.07%
169,068
-137,582
-45% -$746K
TBIO
74
DELISTED
TRANGSGENOMIC INC
TBIO
$838K 0.07%
2,207,500
– –
AVNR
75
PUT
DELISTED
AVANIR PHARMACEUTICALS, INC CL A
AVNR
$816K 0.07%
+193,000
New +$915K
1 2
3
4 5

Similar funds

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
TAM
Todd Asset Management Louisville, Kentucky $5.11B AUM 34.73% 1-Year Est. Return
CIA
Choate Investment Advisors Boston, Massachusetts $5.11B AUM 17.2% 1-Year Est. Return
AC
AKO Capital London, United Kingdom $5.11B AUM 2.56% 1-Year Est. Return
EIC
Equity Investment Corp Atlanta, Georgia $5.11B AUM 8.63% 1-Year Est. Return
CIC
Carnegie Investment Counsel Pepper Pike, Ohio $5.13B AUM 22.98% 1-Year Est. Return
CS
Cannell & Spears New York $5.1B AUM 31.77% 1-Year Est. Return
NC
Nicholas Company Milwaukee, Wisconsin $5.1B AUM 8.43% 1-Year Est. Return

Perceptive Advisors's Q3 2013 Portfolio in Review

As of Q3 2013, Perceptive Advisors held 137 positions worth $1.23B, up 24% from $992M the previous quarter. Its ten largest holdings account for 61% of the portfolio.

Perceptive Advisors deployed $116M of net new capital in Q3 2013, opening 51 new positions and adding to 28 existing holdings. Its largest new stake was ONYX PHARMACEUTICALS INC: 556,944 shares worth $69.5M.

By sector, the portfolio is most concentrated in Healthcare at 77% of assets, down from 80% a quarter earlier, followed by Financials and Consumer Staples.

On the sell side, the largest reduction was Aegerion Pharmaceuticals, an estimated $106M trimmed.

  • Perceptive Advisors's largest Q3 2013 buy was ONYX PHARMACEUTICALS INC: 556,944 shares worth $69.5M.
  • Perceptive Advisors added most to Celgene Corp in Q3 2013, an estimated $37.6M increase.
  • Perceptive Advisors's biggest Q3 2013 reduction was Aegerion Pharmaceuticals, cutting an estimated $106M.
  • Perceptive Advisors fully exited Biogen in Q3 2013, selling an estimated $49.8M.
  • Perceptive Advisors's ten largest holdings make up 61% of its $1.23B portfolio in Q3 2013.
  • Perceptive Advisors opened 51 new positions and closed 23 in Q3 2013.
  • Perceptive Advisors's portfolio value rose 24% quarter-over-quarter to $1.23B.

Based on Perceptive Advisors's 13F filing for Q3 2013, filed 14 Nov 2013.